The pharmaceutical companies did not disclose the financial terms of the deal.
Under the agreement, the companies will manage regulatory approval processes and commercial operations within their allocated territories.
GEBRO will direct product supply and commercialisation across Europe and selected global markets, anchored by Spain.
Spektus will oversee supply and commercialisation across Africa, the Americas, and Asia, relying on an established network of regional pharmaceutical partners.
ActraFlex combines paracetamol and tramadol into a formulation engineered to provide sustained release using a twice-daily dosing regimen.
The therapy integrates Spektus’ AmyloFlex drug-delivery technology with GEBRO’s Diliban product that already maintains an established commercial presence in Spain.
GEBRO Holding managing director Christian Kollenz said: “GEBRO brings deep expertise in pain management and a strong foundation with Diliban in Europe.
“Together with Spektus’ established commercialisation partner network, we believe ActraFlex has the potential to become an important global product in pain management.”
Spektus Pharma CEO Zarvaan Merchant said: “Our partnership with GEBRO highlights the potential of Spektus’ proprietary AmyloFlex technology to create differentiated speciality medicines from established products and brands.
“Building on GEBRO’s successful commercialisation of Diliban in Europe, we see strong commercial potential for ActraFlex across the Americas, Africa and Asia.”
GEBRO has developmental and commercialisation experience in specialised medicines.
The organisation places a particular therapeutic focus on rheumatoid arthritis and pain management, conducting business across multiple European and global markets via its own corporate affiliates and external partner networks.
Spektus Pharma creates differentiated medicines by applying drug-delivery formulation platforms to established active pharmaceutical ingredients and products.